What does FDA approval of Sanofi’s Tzield mean for pediatric stage 3 diabetes?

The FDA has approved Sanofi’s Tzield (teplizumab) for treating children already diagnosed with stage 3 autoimmune diabetes, expanding its use beyond prevention. The move opens a new pediatric therapeutic market for Sanofi and highlights the agency’s willingness to revisit complex immune‑modulating biologics after internal regulatory disputes.